Amarin Corp. (NASDAQ:AMRN) is trading sharply lower this morning on reports that members of management and the Board sold company stock and exercised options after the FDA’s approval of Vascepa, the company’s treatment for high triglycerides. Given the billion-dollar potential for Vascepa, particularly in combination with cholesterol-lowering statin drugs, Wall Street analysts have price targets averaging $25 per share, more than double today’s price for AMRN. Management has executed well despite selling stock along the way, suggesting that (more…)